Home / News / Events / Events detail
Viva Biotech was a co-organizer of the 2023 JPMorgan Week Reaching Beyond the Low-Hanging Fruits in Drug Discovery Forum and was also invited to participate in the 2023 China Focus Global Life Science Summit and the 2022 Qingsong Annual Meeting. The following provides an overview of the insights shared by Viva's experts at these events.
2023 JPMorgan Week丨Reaching Beyond the Low-Hanging Fruits in Drug Discovery Forum
On January 10, 2023, the Reaching Beyond the Low-Hanging Fruits in Drug Discovery Forum was held at the JPMorgan Convention Center in San Francisco, jointly hosted by eChinaHealth and Viva Biotech. Yinghong Gao, Vice President of Business Development at Viva and Venture Partner at VBI, moderated the first part of the panel, while Sally Wang Liang, Venture Partner at VBI, moderated the second part of the panel.
The first part of the forum focused on presentations and discussions on the use of state-of-the-art biophysical technology platforms to overcome the challenges posed by non-druggable targets and new drug paradigms.
The second part of the forum covered incubation of startups, biotech investments, and partnerships with pharmaceutical companies. Additionally, seven VBI investment and incubation startups participated in the event and discussed their company roadshows around developing the drugs of the future.
2023 ChinaFocus Global Life Science Summit
The 2023 China Focus Global Life Science Summit was held on January 9, 2023, at the National Innovation Center par Excellence. The event explored cross-border cooperation in the global life sciences sector, the cooperation strategy of multinational pharmaceutical companies in China, the innovation and internationalization of local pharmaceutical companies, the collaboration of foreign-related institutions, embassies and consulates, and the development of biotechnology.
In the second panel, entitled "The Path of Global Development of Pharmaceutical Companies under the Strategic Layout of 'Innovation + Internationalization'", Dr. Han Dai, CIO of Viva Biotech and Head of Viva BioInnovator, engaged in discussions with several guests.
2022 Qingsong Annual Meeting
On December 30, 2022, the Qingsong Club held its annual meeting, which focused on the key topics of new drug investment, R&D, BD collaboration, commercialization, and the strategic direction of the company, all of which are topics that are very important for founders and investors in 2023. Dr. Han Dai, CIO of Viva Biotech and Head of Viva BioInnovator, was invited to participate in the session on "Cellular Antibody Investment and Commercialization in Primary and Secondary Markets."
Dr. Dai provided an overview of Viva BioInnovator's global biopharmaceutical investment portfolio, which focuses on the field of antibody and cell therapy, including new target monoclonal antibodies, dual antibodies, immune cytokines, ADC, CAR-NK, and TCR-T in multi-disease areas. He also discussed the company's investment strategy, which involves a multi-dimensional assessment of startups' science and technology, founding teams, clinical needs, and market prospects.
Copyright © Viva Biotech All Rights Reserved. 沪ICP备19036061号